Pelvic exenteration for vulvar cancer: contemporary outcomes from a multinational cohort study

IntroductionWomen with vulvar cancer are considerably older than those with other gynaecological malignancies, raising concerns about the tolerability of radical surgery. Yet, for locally advanced or recurrent disease, pelvic exenteration may be the only curative option. Robust evidence to guide decision-making in this population is lacking.Material and methodsThis multicentre observational cohort study used data from the COREPEX registry including women who underwent anterior or total pelvic exenteration between 2005 and 2023 across 20 European tertiary referral centres. The primary outcome was overall survival (OS); secondary outcomes were progression-free survival (PFS) and major postoperative complications. Associations were assessed using multivariable Cox and binomial regression models adjusted for relevant covariates.ResultsAmong 861 women, 79 (9.2%) had vulvar cancer. Median follow-up was 49 months for OS and 40 months for PFS. Women with vulvar cancer were older and more often overweight. Five-year OS was 32% (95% CI, 19–46) in vulvar cancer versus 29% (95% CI, 25–34) in other cancers, adjusted HR 1.05 (95% CI, 0.75–1.46). Five-year PFS was 34% versus 29%, adjusted HR 0.96 (95% CI, 0.69–1.34). Major complications occurred in 33% vs 29%, adjusted RR 1.12 (95% CI, 0.77–1.58). Lymph node metastases, positive margins, and recurrent or persistent disease independently predicted poorer survival.ConclusionDespite their older age, women with vulvar cancer had survival and morbidity comparable to those with other gynaecological malignancies. These findings support pelvic exenteration as a curative option for selected women with vulvar cancer when complete resection is feasible.